Systematic review and meta-analysis of efficacy and safety of silodosin in treatment of benign prostatic hyperplasia patients with lower urinary tract symptoms
Abstract
Background: Silodosin is a new high-selective α1A-adrenoceptors antagonist. A systematic review of literature and meta-analysis were performed to compare the clinical efficacy and safety outcomes of silodosin with placebo, tamsulosin, naftopidil and alfuzosin in treating benign prostatic hyperplasia (BPH) males with lower urinary tract symptoms (LUTS). Materials and Methods: We systematically searched literature among EMBASE, PubMed, Cochrane Library, ScienceDirect and Web of Science databases until April 2019. 18 related randomized controlled trials were included according to eligibility criteria. Random-effects model were applied for data analysis. Results: 5,985 patients were included in our study. Silodosin presented superiority to placebo in improving LUTS and better efficacy than tamsulosin and naftopidil in improving IPSS void subscore and post-void residual urine volume with statistically significance (all P values < 0.05). Greater QoL index improvement were found in silodosin than alfuzosin groups (MD = -0.44, 95%CI: [-0.83, -0.05], P = 0.03) while no differences in total IPSS score and Qmax changes between these two groups. Retrograde ejaculation was significantly frequent in silodosin than placebo, tamsulosin and naftopidil groups (all P values < 0.05). Besides, silodosin increased incidence of upper respiratory tract infection compared to tamsulosin groups (RR = 0.69, 95%CI: [0.50, 0.96], P = 0.03). A higher rate of nasal congestion (RR = 7.76, 95%CI: [1.80,…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 5,985 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.